← Leaderboards
Adrian U Wiestner
Heart, Lung, And Blood Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsResponseEventMolecularSystems BiologyGene Expression ProfilingTumorNeoplastic CellBone MarrowSamplingResistanceBloodConduct Clinical TrialsChronic Lymphocytic LeukemiaPathway InteractionsInnovative TherapyNovel StrategiesLymph NodesPharmaceutical PreparationsClinical TrialsRefractoryB-LymphocytesSignal Transduction
Grant awards (51)
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$3,407,099
ZIA · FY2025 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$2,271,399
ZIA · FY2025 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$3,201,150
ZIA · FY2024 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$1,371,922
ZIA · FY2024 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$2,519,818
ZIA · FY2023 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$1,679,879
ZIA · FY2023 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$1,663,921
ZIA · FY2022 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$1,663,921
ZIA · FY2022 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$1,461,574
ZIA · FY2021 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$1,461,574
ZIA · FY2021 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$2,408,401
ZIA · FY2020 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$803,050
ZIA · FY2020 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$2,312,651
ZIA · FY2019 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$1,023,663
ZIA · FY2019 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$65,185
ZIA · FY2019 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$2,898,518
ZIA · FY2018 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$1,324,138
ZIA · FY2018 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$199,581
ZIA · FY2018 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$1,624,315
ZIA · FY2017 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$804,816
ZIA · FY2017 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$257,483
ZIA · FY2017 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$1,602,982
ZIA · FY2016 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$457,995
ZIA · FY2016 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$228,997
ZIA · FY2016 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$1,252,072
ZIA · FY2015 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$626,036
ZIA · FY2015 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$208,679
ZIA · FY2015 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$1,276,483
ZIA · FY2014 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$425,494
ZIA · FY2014 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$425,494
ZIA · FY2014 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$1,131,849
ZIA · FY2013 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$568,871
ZIA · FY2013 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$193,552
ZIA · FY2013 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$965,559
ZIA · FY2012 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$482,780
ZIA · FY2012 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$160,927
ZIA · FY2012 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$742,234
ZIA · FY2011 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$556,675
ZIA · FY2011 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$556,675
ZIA · FY2011 · HL · contact PI
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy$501,567
ZIA · FY2010 · HL · contact PI
Immunotherapy of low grade lymphoid malignancies$376,175
ZIA · FY2010 · HL · contact PI
Novel therapies for Mantle Cell Lymphoma: targets, mechanisms, and prognosis$376,175
ZIA · FY2010 · HL · contact PI
Gene Expression Profiling/Chronic Lymphocytic Leukemia$836,258
ZIA · FY2009 · HL · contact PI
Molecular Effects of Bortezomib in Mantle Cell Lymphoma$566,584
ZIA · FY2009 · HL · contact PI
Gene Expression Profiling/Chronic Lymphocytic Leukemia$986,494
Z01 · FY2008 · HL · contact PI
Molecular Effects of Bortezomib in Mantle Cell Lymphoma$657,663
Z01 · FY2008 · HL · contact PI
Gene Expression Profiling/Chronic Lymphocytic Leukemia$1,527,126
Z01 · FY2007 · HL · contact PI
Molecular Effects of Bortezomib in Mantle Cell Lymphoma$1,018,084
Z01 · FY2007 · HL · contact PI
Gene Expression Profiling/Chronic Lymphocytic Leukemia$0
Z01 · FY2006 · HL · contact PI
Molecular Effects of Bortezomib in Mantle Cell Lymphoma$0
Z01 · FY2006 · HL · contact PI
Gene Expression Profiling/Chronic Lymphocytic Leukemia$0
Z01 · FY2005 · HL